Experience With More Than 1,000 Holmium Laser Prostate Enucleations for Benign Prostatic Hyperplasia
Methodist Hospital Institute for Kidney Stone Disease, Indianapolis, Indiana 46202, USA. The Journal of urology
(Impact Factor: 4.47).
03/2010; 183(3):1105-9. DOI: 10.1016/j.juro.2009.11.034
Holmium laser prostate enucleation is a contemporary treatment for benign prostatic hyperplasia. We report our experience with more than 1,000 procedures.
From June 1998 to March 2009 we performed 1,065 holmium laser prostate enucleations. After receiving institutional review board approval we retrospectively reviewed the database. Reported short-term, intermediate term and long-term results are 0 to 6, 6 to 12 and greater than 12 months, respectively.
Bladder stones were present in 50 patients (4.7%) and 87 of the 717 (12.1%) with laboratory studies available had renal insufficiency. Preoperative urinary retention was present in 411 cases (38.7%). Significant preoperative stress and urge incontinence was noted in 8 and 16 patients, respectively. Mean transrectal ultrasound prostate volume was 99.3 gm (range 9 to 391). Mean preoperative American Urological Association symptom score was 20.3 (range 1 to 35) and maximum urinary flow was 8.4 cc per second (range 1.1 to 39.3). Intraoperative or postoperative complications occurred in 24 cases (2.3%). Mean followup was 287 days (range 6 to 3,571). At short-term, intermediate term and long-term followup the mean symptom score was 8.7, 5.9 and 5.3, and maximum urinary flow was 17.9, 19.5 and 22.7 cc per second, respectively. At the most recent followup 3 patients (0.3%) were in urinary retention. One patient with maximum urinary flow 20 cc per second required a second procedure for bleeding prostatic regrowth. Urethral stricture was noted in 9 (0.9%), 11 (1.3%), 4 (1.3%) and 0 patients, and bladder neck contracture was found in 0, 7 (0.8%), 4 (1.3%) and 5 (6.0%) at short-term, intermediate term, long-term and greater than 5-year followup, respectively. At the most recent followup significant stress and urge incontinence was noted in 9 and 6 patients, respectively.
Holmium laser prostate enucleation is safe and effective for benign prostatic hyperplasia. The complication rate is low, and incontinence and the need for ancillary procedures are rare for holmium laser prostate enucleation with durable long-term results.
Available from: Ahmed R El-Nahas
- "In a large series of HOLEP, the perioperative complication rate was 2.3% , with a transfusion rate of 0.5%, a mean hospital stay of 31.6–32 h and a mean catheter duration of 19.1–33.6 h . "
[Show abstract] [Hide abstract]
ABSTRACT: Objective: To assess the perioperative morbidity of transvesical open
prostatectomy (OP) and its predictors as a treatment for benign prostatic hyperplasia
(BPH), and to update knowledge about the morbidity of OP using a standardised
morbidity scale (Clavien), thus providing a platform for comparison with the newly
Patients and methods: We retrospectively review men with BPH who were treated
with transvesical OP between April 2002 and December 2012. Preoperative patients’
data were reviewed for relevant variables. Operative details, the postoperative
course, and 30-day relevant data were assessed. The study cohort was stratified
based on the resected prostate weight, with group 1 having a resected weight of
6120 g and group 2 >120 g.
Results: The review identified 163 patients. The mean (SD, range) duration of
catheterisation after OP was 7.9 (2.2, 5–20) days and the duration of hospitalisation
after OP was 8.1 (1.8, 5–15) days; both were significantly longer in group 2. All
patients were able to void spontaneously by the first follow-up visit. Of 163 OP procedures,
there were 106 perioperative complications in 69 (42.3%). Low-grade complications
(grade 62) included 38 (45.2%) and 53 (67%) in groups 1 and 2,respectively (P = 0.8). High-grade complications (P3) included 3 (3.5%) and 12
(15.1%) in groups 1 and 2, respectively (P = 0.02). The blood transfusion rate
was 24.5%, the perioperative mortality rate was 1.2% and the re-admission rate
within the first 30 days after OP was 1.2%. High-grade complications were significantly
associated with a greater resected prostate weight (odds ratio 1.08, 95% CI
1.001–1.17, P = 0.046).
Conclusion: The OP procedure is associated with a significant perioperative morbidity
that correlated significantly with the resected prostate weight, especially for
Arab Journal of Urology 12/2013; 11(4). DOI:10.1016/j.aju.2013.06.003
Available from: Hahn-Ey Lee
- "The detailed equipment for HoLEP is similar in all institutional groups [10-13,19,20,22-25,29,38-41]. Generally, HoLEP surgeons use a 60 to 100-W holmium laser (Versapulse, Lumenis Ltd., Yokneam, Israel) with a power setting of 2 to 2.4 J at 25 to 50 Hz [7,10,20,26,39-41]. "
[Show abstract] [Hide abstract]
ABSTRACT: Holmium laser enucleation of the prostate (HoLEP) is a minimally invasive procedure and a size-independent treatment for benign prostatic hyperplasia with excellent long-term surgical outcome. HoLEP has become an alternative to conventional transurethral resection of the prostate or open prostatectomy owing to its efficacy and safety. Although HoLEP is known to have a steep learning curve, very few articles have addressed the technical aspects of HoLEP. Herein, we described detailed techniques and tips for HoLEP as performed at Seoul National University Hospital in a step-by-step manner with extensive review of the literature.
Korean journal of urology 09/2013; 54(9):570-579. DOI:10.4111/kju.2013.54.9.570
Available from: PubMed Central
- "Although transurethral resection of the prostate (TURP) is considered the gold standard for surgical treatment of BPH, other new techniques for the surgical treatment of BPH have been introduced. Among the surgical techniques for BPH, holmium laser enucleation of the prostate (HoLEP) has become an important treatment modality, and several studies have shown that HoLEP is safe and effective for BPH of any size [2-5]. Improvement of the patient's QoL is one of the aims of HoLEP, and a significant improvement in QoL after HoLEP has been reported in some studies [6,7]. "
[Show abstract] [Hide abstract]
ABSTRACT: The aim of this study was to investigate the preoperative factors related to early quality of life (QoL) in patients with benign prostatic hyperplasia after holmium laser enucleation of the prostate (HoLEP) during the surgeon's learning curve.
The medical records of 82 patients with a follow-up period of at least 3 months who were treated with HoLEP during the time of a surgeon's learning curve were analyzed retrospectively. We divided the patients into two groups on the basis of the QoL component of the International Prostate Symptom Score (IPSS) 3 months after HoLEP: the high QoL group (IPSS/QoL≤3) and the low QoL group (IPSS/QoL≥4). Preoperative factors in each group were compared, including prostate volume, prostate-specific antigen, history of acute urinary retention (AUR), urgency incontinence, IPSS, and urodynamic parameters. Detrusor underactivity was defined as a bladder contractility index less than 100 on urodynamic study.
A total of 61 patients (74.3%) had a high QoL, whereas 21 (25.7%) had a low QoL. A history of AUR, detrusor pressure on maximal flow (PdetQmax), bladder outlet obstruction grade, bladder contractility index, and detrusor underactivity were associated with postoperative QoL in the univariate analysis. In the multivariate analysis, a history of AUR and PdetQmax were independent factors affecting postoperative QoL.
A history of AUR and bladder contractility affect early QoL, and preoperative urodynamic study plays an important role in the proper selection of patients during the HoLEP learning curve.
International neurourology journal 06/2013; 17(2):83-9. DOI:10.5213/inj.2013.17.2.83 · 1.06 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.